D. Medical Issued U.S. Patent No. 8,021,334
21 Setembro 2011 - 8:45AM
D. Medical Industries Ltd. (Nasdaq:DMED) (TASE:DMED) ("D. Medical"
or the "Company"), a medical device company engaged through its
subsidiaries in the research, development, manufacture and sale of
innovative products for diabetes treatment and drug delivery,
announced today that it has been granted U.S. Patent No. 8,021,334,
entitled "Drug Delivery Device and Method."
This patent protects innovative valve technology that allows
safe and reliable administration of a desired amount of insulin.
Amongst other features, the technology is able to detect
malfunctions that may lead to over or under administration. It
comprises an integral part of D. Medical's proprietary
Intellispring™ and Total Line Control™ systems, which are at the
heart of its "Spring™ Zone" and "Spring™ Hybrid" insulin pumps.
Hezkiah Tsoory, D. Medical's Chief Operating Officer, commented,
"As we continue to work toward the commercialization of our Spring
pump technology, it is important that the many innovations that
define these products are well protected. This U.S. patent issuance
serves to strengthen D. Medical's already formidable intellectual
property estate."
About D. Medical
D. Medical is a medical device company engaged through its
subsidiaries in the research, development, manufacture and sale of
innovative products for diabetes treatment and drug delivery. D.
Medical has developed durable and semi-disposable insulin pumps,
which continuously infuse insulin into a patient's body, using its
proprietary spring-based delivery technology. D. Medical
believes that its spring-based delivery mechanism is cost-effective
compared to the motor and gear train mechanisms that drive
competitive insulin pumps and also allows it to incorporate certain
advantageous functions and design features in its insulin
pumps. D. Medical has also developed an infusion set for
insulin pumps and is focusing its research and development efforts
on the development of next generation insulin pumps and a device
that will combine a continuous glucose monitoring system and an
insulin pump on the same patch. For more information, please
visit http://www.dmedicalindustries.com (corporate) and
http://www.springnow.com (healthcare professionals, patients and
care givers).
Forward-Looking Statements
This press release contains forward-looking statements (as
defined by the Israeli Securities Law, 1968, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended) that involve risks and
uncertainties. These statements include forecasts, goals,
uncertainties and assumptions and relate, inter alia, to D.
Medical's future expectations in connection with its level of sales
and cost of sales, manufacturing volumes, the cost-effectiveness of
its spring-based design, target markets, regulatory approvals and
timing of markets penetration. The forward-looking statements are
based on D. Medical's current expectations and beliefs which are
based on, among other things, its analysis of publicly available
information and market research reports. All forward-looking
statements are subject to certain risks, uncertainties and
assumptions that could cause actual results to differ materially
from those described in the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the impact of
general economic conditions, competitive products, product demand,
product performance, the performance of D. Medical's contract
manufacturer and distributors, regulatory trends and approvals and
healthcare reform legislation. If one or more of these risks and/or
uncertainties materialize, or if the underlying assumptions prove
to be incorrect, D. Medical's actual results, performance or
achievements could differ materially from those expressed in, or
implied by, any such forward-looking statements or results which
are based upon such assumptions. No assurances can be given that
any of the events anticipated by the forward-looking statements
will transpire or occur, or of any of them will transpire or occur,
what impact it will have on D. Medical's results of operations or
financial condition. D. Medical does not undertake to update any
forward-looking statements.
CONTACT: Company Contact:
Amir Loberman
Chief Financial Officer
D. Medical Industries Ltd
T: +972-73-2507135
info@springnow.com
North American Investor Contact:
Stephen Kilmer
T: 212-618-6347
stephen@dmedicalindustries.com
Israeli Investor Relations
Iris Lubitch
T: 972-775538007
Iris@EffectiveIR.co.il
D. Medical Industries Ltd. - Ordinary Shares (MM) (NASDAQ:DMED)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
D. Medical Industries Ltd. - Ordinary Shares (MM) (NASDAQ:DMED)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024